| Literature DB >> 32655262 |
Vanessa A Areco1, Romina Kohan1, Germán Talamoni1, Nori G Tolosa de Talamoni2, María E Peralta López1.
Abstract
Ca2+ has an important role in the maintenance of the skeleton and is involved in the main physiological processes. Its homeostasis is controlled by the intestine, kidney, bone and parathyroid glands. The intestinal Ca2+ absorption occurs mainly via the paracellular and the transcellular pathways. The proteins involved in both ways are regulated by calcitriol and other hormones as well as dietary factors. Fibroblast growth factor 23 (FGF-23) is a strong antagonist of vitamin D action. Part of the intestinal Ca2+ movement seems to be vitamin D independent. Intestinal Ca2+ absorption changes according to different physiological conditions. It is promoted under high Ca2+ demands such as growth, pregnancy, lactation, dietary Ca2+ deficiency and high physical activity. In contrast, the intestinal Ca2+ transport decreases with aging. Oxidative stress inhibits the intestinal Ca2+ absorption whereas the antioxidants counteract the effects of prooxidants leading to the normalization of this physiological process. Several pathologies such as celiac disease, inflammatory bowel diseases, Turner syndrome and others occur with inhibition of intestinal Ca2+ absorption, some hypercalciurias show Ca2+ hyperabsorption, most of these alterations are related to the vitamin D endocrine system. Further research work should be accomplished in order not only to know more molecular details but also to detect possible therapeutic targets to ameliorate or avoid the consequences of altered intestinal Ca2+ absorption. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Ca2+ absorption; Dietary calcium; Hormones; Paracellular pathway; Pathological alterations; Physiological conditions; Transcellular pathway
Mesh:
Substances:
Year: 2020 PMID: 32655262 PMCID: PMC7327788 DOI: 10.3748/wjg.v26.i24.3344
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Effects of hormones on intestinal Ca2+ absorption. Calcitriol stimulates the transcellular and paracellular absorptive pathways by inducing the expression of genes and proteins involved in Ca2+ transport and modifying the permeability of tight junctions. Thyroid hormones enhance the genomic actions of calcitriol whereas glucocorticoids inhibit the transcellular pathway by affecting the expression of Ca2+ transporting proteins. Fibroblast growth factor inhibits the intestinal Ca2+ absorption antagonizing 1,25(OH)2D3 action. Growth hormone enhances the intestinal Ca2+ absorption through vitamin D dependent and independent mechanisms. PMCA1b: Plasma membrane Ca2+-ATPase; CB9k: Calbindin 9k; Cav1.3: Ca2+ channel voltage-dependent L type alpha 1D subunit; TRPV5: Transient receptor potential vanilloid 5; TRPV6: Transient receptor potential vanilloid 6; CLDNs 2, 12 and 15: Claudins 2, 12 and 15; NCX1: Na+/Ca2+ exchanger; 1,25(OH)2D3: Calcitriol; FGF-23: Fibroblast growth factor; GH: Growth hormone; GC: Glucocorticoids; T4: Thyroxine; TJ: Tight junction; VDR: Vitamin D receptor.
Effects of pro-oxidant conditions on intestinal Ca2+absorption and associated parameters
| BSO[ | Inhibition of IAP activity | Decrease in GSH content | GSH administration normalized intestinal Ca2+ absorption | Not evaluated |
| MEN[ | Decrease in PMCA1b gene-protein expression and activity. Decrease in CB D28k and CLDN 2 gene-protein expression | Depletion of GSH content; Increase in ROS and protein carbonyls; Enhancement in SOD and CAT activity | QT, MEL and GLT administration normalized intestinal Ca2+ absorption and associated parameters | Activation of intrinsic and extrinsic pathways |
| NaDOC[ | Decrease in PMCA1b mRNA Inhibition of PMCA1b, CBD28k and NCX1 protein expression | Depletion of GSH content; Increase in ROS and activity of SOD, CAT and GPx; Increase in iNOS protein expression and NO• content | QT and UDCA administration avoided the inhibition of intestinal Ca2+ absorption caused by NaDOC | Activation of intrinsic and extrinsic pathway |
| Diabetes[ | Enhancement in expression of NCX1, PMCA1b and TRPV6 proteins and CLDN 2 gene expression | Decrease in GSH content; Increase in SOD activity and ROS levels | Insulin treatment restored redox state and intestinal Ca2+ absorption | Not evaluated |
| Metabolic syndrome[ | Decrease in TRPV6, PMCA1b, CB D9k, CLDN 2, CLDN 12 and VDR protein expression; Decrease in IAP activity | Enhancement in protein carbonyls, NO• levels and nitrotyrosine content in proteins; Decrease in SOD and CAT activity | Administration of NAR prevented the reduction of intestinal Ca2+ absorption caused by fructose-rich diet | Not evaluated |
BSO: DL-buthionine-S, R-sulfoximine; CAT: Catalase; CB D28k: Calbindin D28k; CB D9k: Calbindin D9k; CLDN 2: Claudin 2; CLDN 12: Claudin 12; GLT: Glutamine; GPX: Glutathione peroxidase; GSH: Glutathione; AP: Alkaline phosphatase; MEL: Melatonin; MEN: Menadione; NaDOC: Sodium deoxycholate; NAR: Naringin; NCX1: Na+/Ca2+ exchanger; NO•: Nitric oxide; PMCA1b: Plasma membrane Ca2+ATPase; QT: Quercetin; SOD: Superoxide dismutase; TRPV6: Transient receptor potential vanilloid type 6; UDCA: Ursodeoxycholic acid; VDR: Vitamin D receptor.